Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPO | P22079 | 5/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23945484 | 0.65 | LPO (0.42) | LPOMEN1KMT2A | |
| SCHEMBL9723505 | 0.59 | LPO (0.41) | LPOMAPTKMT2ALMNACYP1A2 | |
| Hydrochloric Acid SCHEMBL14244520 | 0.56 | LPO (0.32) | LPO | |
| SCHEMBL11565383 | 0.55 | — | — | |
| SCHEMBL24205202 | 0.52 | ALDH1A1 (0.36) | LPOKDM4EMEN1MAPTKMT2A | |
| SCHEMBL149432 | 0.50 | — | — | |
| Benzene SCHEMBL6482650 | 0.42 | TSHR (0.50) | LMNACYP1A2 | |
| Alcohol SCHEMBL27265072 | 0.42 | ALDH1A1 (0.67) | — | |
| Alcohol SCHEMBL27691654 | 0.42 | — | — | |
| Propane SCHEMBL8762642 | 0.42 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100010049-A1 | Novel Tyrosinase inhibitors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-01-14 | — | — | US | claimed |
| US-20100010049-A1 | Novel Tyrosinase inhibitors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010049-A1 | Novel Tyrosinase inhibitors and pharmaceutical/cosmetic applications thereof | TYR, MITF, MAOA | LPO 22/4885KDM4E 1950/4885MEN1 3670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.